Logo image of OVID

OVID THERAPEUTICS INC (OVID) Stock Overview

NASDAQ:OVID - US6904691010 - Common Stock

1.14 USD
+0.11 (+10.68%)
Last: 8/25/2025, 8:00:02 PM
1.16 USD
+0.02 (+1.75%)
Pre-Market: 8/26/2025, 4:33:16 AM

OVID Key Statistics, Chart & Performance

Key Statistics
52 Week High1.47
52 Week Low0.24
Market Cap81.07M
Shares71.11M
Float59.51M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.53
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO05-05 2017-05-05
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


OVID short term performance overview.The bars show the price performance of OVID in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 100 200 300

OVID long term performance overview.The bars show the price performance of OVID in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of OVID is 1.14 USD. In the past month the price increased by 116.11%. In the past year, price increased by 0.88%.

OVID THERAPEUTICS INC / OVID Daily stock chart

OVID Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.6 366.65B
AMGN AMGEN INC 13.23 155.30B
GILD GILEAD SCIENCES INC 14.75 141.64B
VRTX VERTEX PHARMACEUTICALS INC 22.96 99.72B
REGN REGENERON PHARMACEUTICALS 12.54 60.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.15B
ARGX ARGENX SE - ADR 73.07 41.45B
ONC BEONE MEDICINES LTD-ADR 6.23 36.69B
INSM INSMED INC N/A 27.12B
BNTX BIONTECH SE-ADR N/A 25.26B
NTRA NATERA INC N/A 22.30B
BIIB BIOGEN INC 8.52 19.99B

About OVID

Company Profile

OVID logo image Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The firm is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. The company is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. The company develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. The company also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Company Info

OVID THERAPEUTICS INC

441 Ninth Avenue, 14Th Floor

New York City NEW YORK 10036 US

CEO: Jeremy M. Levin

Employees: 23

OVID Company Website

OVID Investor Relations

Phone: 12127764381

OVID THERAPEUTICS INC / OVID FAQ

What is the stock price of OVID THERAPEUTICS INC today?

The current stock price of OVID is 1.14 USD. The price increased by 10.68% in the last trading session.


What is the ticker symbol for OVID THERAPEUTICS INC stock?

The exchange symbol of OVID THERAPEUTICS INC is OVID and it is listed on the Nasdaq exchange.


On which exchange is OVID stock listed?

OVID stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OVID THERAPEUTICS INC stock?

12 analysts have analysed OVID and the average price target is 3.47 USD. This implies a price increase of 204.21% is expected in the next year compared to the current price of 1.14. Check the OVID THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OVID THERAPEUTICS INC worth?

OVID THERAPEUTICS INC (OVID) has a market capitalization of 81.07M USD. This makes OVID a Micro Cap stock.


How many employees does OVID THERAPEUTICS INC have?

OVID THERAPEUTICS INC (OVID) currently has 23 employees.


Is OVID THERAPEUTICS INC (OVID) expected to grow?

The Revenue of OVID THERAPEUTICS INC (OVID) is expected to grow by 581.37% in the next year. Check the estimates tab for more information on the OVID EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OVID THERAPEUTICS INC (OVID) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OVID THERAPEUTICS INC (OVID) stock pay dividends?

OVID does not pay a dividend.


When does OVID THERAPEUTICS INC (OVID) report earnings?

OVID THERAPEUTICS INC (OVID) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of OVID THERAPEUTICS INC (OVID)?

OVID THERAPEUTICS INC (OVID) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.53).


What is the Short Interest ratio of OVID THERAPEUTICS INC (OVID) stock?

The outstanding short interest for OVID THERAPEUTICS INC (OVID) is 2.71% of its float. Check the ownership tab for more information on the OVID short interest.


OVID Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to OVID. When comparing the yearly performance of all stocks, OVID is one of the better performing stocks in the market, outperforming 98.35% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OVID Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to OVID. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OVID Financial Highlights

Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -23.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.58%
ROE -42.13%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-150%
Sales Q2Q%3611.24%
EPS 1Y (TTM)-23.26%
Revenue 1Y (TTM)44.5%

OVID Forecast & Estimates

12 analysts have analysed OVID and the average price target is 3.47 USD. This implies a price increase of 204.21% is expected in the next year compared to the current price of 1.14.

For the next year, analysts expect an EPS growth of -43.56% and a revenue growth 581.37% for OVID


Analysts
Analysts86.67
Price Target3.47 (204.39%)
EPS Next Y-43.56%
Revenue Next Year581.37%

OVID Ownership

Ownership
Inst Owners42.94%
Ins Owners5.68%
Short Float %2.71%
Short Ratio0.77